Predictors of Inappropriately Rapid Coronary Lesion Progression in Patients Undergoing Percutaneous Coronary...

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Atherosclerosis Research

Background:

• Percutaneous coronary intervention (PCI) patients can exhibit accelerated atherosclerotic plaque progression in untreated vessels.
• This rapid progression is hypothesized to be driven by intra-lesion bleeding, not solely de novo atherosclerosis.
• Investigating factors contributing to accelerated coronary diameter narrowing is crucial.

Purpose of the Study:

• To explore potential factors contributing to accelerated atherosclerotic plaque progression in nontreated coronary segments post-PCI.
• To test the hypothesis that intra-lesion bleeding plays a central role in this phenomenon.
• To identify procedural or laboratory factors associated with rapid plaque progression.

Main Methods:

• Review of 65 interventional procedures and staged PCIs.
• Coronary tree segmentation (American Heart Association 16 segments) with stenosis grading.
• Analysis of demographic, procedural, and laboratory data, including eptifibatide administration and white blood cell counts.

Main Results:

• Intra-procedural eptifibatide administration was associated with rapid progression of coronary lesions in nontreated segments.
• Elevated white blood cell count before the index procedure showed a trend toward association with rapid plaque progression.
• Rapidly progressing lesions were identified between sequential angiographies.

Conclusions:

• Treatment with a glycoprotein IIb/IIIa inhibitor during PCI may be linked to accelerated short-term progression of nontreated lesions.
• This anti-aggregation therapy might facilitate plaque hemorrhage, accelerating coronary atherosclerosis in eroded plaques.
• Findings suggest a potential mechanism for plaque progression beyond natural development post-PCI.